Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2017
June 2017, Vol 8, No 3
June 2017, Vol 8, No 3
Longest Follow-Up in Patients with NSCLC Who Responded to Immunotherapy with Nivolumab
By
Phoebe Starr
Immunotherapy
,
Personalized Medicine
June 2017, Vol 8, No 3
Washington, DC—In the longest follow-up on single-agent nivolumab (Opdivo) to date, 5-year overall survival was 16% in patients with advanced non–small-cell lung cancer (NSCLC) in the updated results of a phase 1b dose-ranging study (CA209-003). This represents a quadrupling of 5-year overall survival with standard platinum doublets, which is approximately 4% for patients with metastatic NSCLC.
Read Article
Higher Readmission Rates After Surgery Not Always Bad in Ovarian Cancer
By
Charles Bankhead
Gynecologic Cancer
June 2017, Vol 8, No 3
National Harbor, MD—A higher readmission rate after surgery had a significant association with improved survival for patients with ovarian cancer, according to 2 studies reported at the 2017 Society of Gynecologic Oncology meeting.
Read Article
ASCO Annual Report 2017: Immunotherapy 2.0 Advance of the Year
By
Eileen Koutnik-Fotopoulos
Value in Oncology
June 2017, Vol 8, No 3
Advances in immunotherapy are benefiting increasing numbers of patients living with cancer. Since 2011, the FDA approved 15 immunotherapies in oncology, including 5 immunotherapy drugs in 2016. This surge of progress using cancer immunotherapy has led the American Society of Clinical Oncology (ASCO) to name “Immunotherapy 2.0” as its cancer advance of the year for a second year in a row.
Read Article
Olaparib Maintenance Has Large Progression-Free Survival Advantage in Relapsed Ovarian Cancer with BRCA Mutation
By
Charles Bankhead
Gynecologic Cancer
June 2017, Vol 8, No 3
National Harbor, MD—A randomized clinical trial of olaparib strengthened the PARP (poly ADP-ribose polymerase) inhibitor’s role as maintenance therapy for patients with ovarian cancer and
BRCA
mutation, demonstrating dramatic improvement in progression-free survival (PFS) versus placebo.
Read Article
New Vaccine Shows Monumental Survival Impact in Metastatic Cervical Cancer
By
Charles Bankhead
Gynecologic Cancer
June 2017, Vol 8, No 3
National Harbor, MD—Patients with recurrent metastatic cervical cancer surpassed all historical standards for 1-year survival when treated with an investigational immunotherapy targeting human papillomavirus (HPV) infection.
Read Article
Rubraca’s Benefit in Ovarian Cancer Hinges on Platinum Status, Previous Therapy
By
Charles Bankhead
Gynecologic Cancer
June 2017, Vol 8, No 3
National Harbor, MD—Patients with relapsed high-grade ovarian cancer with
BRCA
mutation derived the greatest benefit from the poly ADP-ribose polymerase (PARP) inhibitor rucaparib (Rubraca) if their disease remained platinum sensitive, a new analysis of a large phase 2 clinical trial showed, as reported at the 2017 Society of Gynecologic Oncology meeting.
Read Article
Letermovir Prophylaxis After Transplant for Cytomegalovirus
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
June 2017, Vol 8, No 3
Orlando, FL—Prophylaxis with letermovir beginning after hematopoietic-cell transplantation (HCT) and lasting through 100 days reduced the risk for clinically significant cytomegalovirus (CMV) infection. Furthermore, letermovir was associated with lower all-cause mortality compared with placebo, reported Francisco M. Marty, MD, Associate Professor of Medicine, Harvard Medical School, Boston, at the 2017 BMT Tandem Meetings.
Read Article
PV-10 Therapy Shows Promise for Hepatic Tumors
By
Walter Alexander
Emerging Therapies
,
Personalized Medicine
June 2017, Vol 8, No 3
Hollywood, FL—A basket study of the oncolytic immunotherapy PV-10 (10% Rose Bengal disodium for injection), which included patients with tumors originating in various locations, showed that data for gastrointestinal lesions were especially encouraging, reported Paul M. Goldfarb, MD, FACS, a surgeon at Oncology Associates of San Diego, CA, at the 2017 Clinical Interventional Oncology annual symposium.
Read Article
Excellent Responses to Atezolizumab in Small Subset of Women with Triple-Negative Breast Cancer
By
Phoebe Starr
Breast Cancer
,
Solid Tumors
,
Personalized Medicine
June 2017, Vol 8, No 3
Washington, DC—Preliminary data show excellent and durable responses to atezolizumab (Tecentriq) in 10% of women with triple-negative breast cancer, one of the most aggressive and difficult-to-treat cancers. Of the responders to atezolizumab, 100% were alive at 1 year compared with only 38% of nonresponders. The trick will be to identify which women will respond to immune checkpoint inhibitor therapy. Thus far, no biomarkers for response have been identified.
Read Article
Impact of Elevated Tumor-Infiltrating Lymphocytes Differs Across Breast Cancer Subtypes
By
Charles Bankhead
Breast Cancer
,
Solid Tumors
,
Personalized Medicine
June 2017, Vol 8, No 3
San Antonio, TX—Concentrations of tumor-infiltrating lymphocytes (TILs) had significant but variable associations with survival in breast cancer, according to 2 large retrospective studies of pathology specimens reported at the 2016 San Antonio Breast Cancer Symposium.
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma